All articles tagged with #phase 2 trial
Vertex Pharmaceuticals announced that its experimental pain drug VX-993 failed to outperform placebo in a Phase 2 trial, leading to the discontinuation of its development as a single-agent for acute pain, though the company will continue testing it for chronic nerve pain in diabetic patients.
Viking Therapeutics' stock soared after positive data from its weight-loss drug trial, making the company an attractive takeover target. Analysts raised price targets and reiterated buy ratings, citing the drug's potential to outperform competitors. The company is also developing a treatment for NASH and plans to discuss next steps with the FDA. The stock has gained 392% year-to-date, outperforming the S&P 500.
Viking Therapeutics' stock doubled after reporting positive results from a Phase 2 trial of its weight-loss drug VK2735, showing statistically significant reductions in body weight at all doses compared to placebo, with patients losing up to 14.7% of their body weight after 13 weeks. The treatment was well-tolerated, and the company plans to discuss next steps with the FDA. The news positions Viking as a potential competitor in the weight-loss drug market, and the company is also developing a treatment for NASH.
Novavax's COVID-Influenza Combination, stand-alone influenza, and high-dose COVID vaccine candidates have demonstrated robust immune responses in a Phase 2 trial. The trial evaluated the safety and effectiveness of different formulations of the vaccine candidates in adults aged 50 through 80. All three vaccine candidates contained Novavax's patented Matrix-M adjuvant and showed reassuring preliminary safety profiles and reactogenicity that was comparable to authorized influenza vaccine comparators. The CIC vaccine candidate achieved both immunoglobulin G (IgG) and neutralizing levels comparable to Novavax's prototype COVID vaccine (NVX-CoV2373).